<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/96BCFB3B-2270-4358-9969-3962B89DE2FF"><gtr:id>96BCFB3B-2270-4358-9969-3962B89DE2FF</gtr:id><gtr:name>Reneuron Limited</gtr:name><gtr:address><gtr:line1>Reneuron,Pencoed Business Park</gtr:line1><gtr:city>Pencoed</gtr:city><gtr:postCode>CF35 5HY</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/96BCFB3B-2270-4358-9969-3962B89DE2FF" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>96BCFB3B-2270-4358-9969-3962B89DE2FF</gtr:id><gtr:name>Reneuron Limited</gtr:name><gtr:address><gtr:line1>Reneuron,Pencoed Business Park</gtr:line1><gtr:city>Pencoed</gtr:city><gtr:postCode>CF35 5HY</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>920929.0</gtr:offerGrant><gtr:projectCost>1315613.0</gtr:projectCost></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>443160.0</gtr:offerGrant><gtr:projectCost>443160.0</gtr:projectCost></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/091DC813-9069-4666-8998-1D89E081C9F2" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>091DC813-9069-4666-8998-1D89E081C9F2</gtr:id><gtr:name>Cell Therapy Catapult Limited</gtr:name><gtr:address><gtr:line1>12th Floor Tower Wing, Guys Hospital, 
Great Maze Pond,</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>SE1 9RT</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>740151.0</gtr:offerGrant><gtr:projectCost>740151.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/2DD53566-84EC-47A5-AF8E-0FD521E55466"><gtr:id>2DD53566-84EC-47A5-AF8E-0FD521E55466</gtr:id><gtr:firstName>Rikki</gtr:firstName><gtr:surname>Arnold</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=102570"><gtr:id>6849845A-2F17-41AB-A5BF-BB05514373B0</gtr:id><gtr:title>Stem cell-derived exosomes for regenerative medicine</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Collaborative R&amp;D</gtr:grantCategory><gtr:grantReference>102570</gtr:grantReference><gtr:abstractText>ReNeuron is a leading UK regenerative medicine company currently conducting clinical trials with a novel

human neural stem cell (hNSC) product for the treatment of stroke and limb ischaemia. These stem cells also

produce small parcels of biologic material called exosomes. CTX-derived exosomes have been found to have

functional properties in laboratory models of cancer, particularly glioblastomas. It may therefore be feasible to

use the exosomes as an alternative class of regenerative medicine that has a long shelf-life and application to a

wide range of diseases. In this project, we will tackle how to purify exosomes in large enough quantities cost-

effectively at scale and then complete preclinical studies for a clinical trial application in glioblastoma. If

successful, our project will benefit patients with the target disease as well as the UK regenerative medicine

industry.</gtr:abstractText><gtr:fund><gtr:end>2019-04-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2016-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>2104240</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">102570</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>